BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives
A strong association between pancreatic cancer and <i>BRCA1</i> and <i>BRCA2</i> mutations is documented. Based on promising results of breast and ovarian cancers, several clinical trials with poly (ADP-ribose) polymerase inhibitors (PARPi) are ongoing for gastrointestinal (G...
Main Authors: | Eleonora Molinaro, Kalliopi Andrikou, Andrea Casadei-Gardini, Giulia Rovesti |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-11-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/11/3346 |
Similar Items
-
An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer
by: Alessandra Anna Prete, et al.
Published: (2022-01-01) -
Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer–Real-World Data from Two Large German Breast Centers
by: Dominik Dannehl, et al.
Published: (2023-07-01) -
BRCA2 reversion mutation confers resistance to olaparib in breast cancer
by: Shinya Yamamoto, et al.
Published: (2023-06-01) -
Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis
by: Yanhui Li
Published: (2023-12-01) -
Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib
by: Gehan Botrus, et al.
Published: (2022-10-01)